Study cites race and socioeconomic factors as influential in NSCLC patient survival rates

October 16, 2017, International Association for the Study of Lung Cancer

New research found race and specific socioeconomic factors to have a significant influence on disparities in the survival rates of non-small cell lung cancer (NSCLC) patients. Dr. Yanyan Lou of the Mayo Clinic in the United States presented these findings today at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan.

While NSCLC patient outcomes have improved over time, the influence of race and socioeconomic factors on these outcomes has historically not been well studied. By using data from the National Cancer Database on NSCLC incident cases from 2004-2013 in the U.S., Dr. Lou and her team sought to determine whether a correlation exists between patients' overall survival (OS) and various socioeconomic factors and race.

Of the more than 1.1 million cases studied, 86.4 percent were White, 10.6 percent were Black, and smaller proportions were Asian and Hispanic. Income was fairly evenly distributed. Additionally, a majority of the cases were individuals who were insured, lived in a metro area and received care at non-academic facilities.

The researchers found that the median overall survival was significantly better for Asians and Hispanics as compared to Whites and Blacks. The range of medians between the highest (Asians) and lowest (Blacks) OS rates was over half a year (6.7 months). Additionally, they found that outcomes were worse when there was a higher rate of comorbidity with other diseases, advanced stage and treatment at a community or low-volume center. Finally, the researchers determined that specific socioeconomic factors were associated with worse outcomes, including lower education levels, lower median income and uninsured status.

Based on this study, the researchers determined that the influence of race and specific socioeconomic factors is significant. In order to ensure fair treatment and patient outcomes, these factors must be considered in the provision of care for NSCLC.

"The study is the largest analysis on the correlation between and and NSCLC outcomes to date," said Dr. Lou. "Our findings indicate that improving outcomes for NSCLC doesn't solely rely on advancements in medicine, but also on ensuring more equitable health care delivery."

Explore further: Racial disparities persist in treatment and survival of early stage lung cancer

Related Stories

Racial disparities persist in treatment and survival of early stage lung cancer

March 16, 2017
Analysis of the largest American cancer database indicates that racial disparities persist in the treatment and outcomes of patients diagnosed with stage I non-small cell lung cancer (NSCLC). Despite increased availability ...

Advanced stage NSCLC patients receiving treatment have better OS than untreated patients

January 18, 2017
Non-small cell lung cancer (NSCLC) patients with advanced disease receiving standard of care treatment have a higher overall survival (OS) than similar patients not receiving treatment.

Foreign-born hispanics have survival advantage in NSCLC

August 22, 2013
(HealthDay)—Compared with non-Hispanic whites (NHWs) and U.S.-born Hispanics, foreign-born Hispanics with non-small-cell lung cancer (NSCLC) have a reduced risk of disease-specific mortality, according to research published ...

Socioeconomic factors—not race or ethnicity—influence survival of younger patients with multiple myeloma

August 22, 2016
Advances in the treatment of multiple myeloma, a cancer that forms in a type of white blood cell, have led to improved survival predominantly among young and white patients, with less of an increase in survival observed in ...

Hispanic lung cancer patients have higher survival than non-Hispanic white patients

September 6, 2012
Analysis of non-small cell lung cancer (NSCLC) patient records in the California Cancer Registry (CCR) database during the 20-year period of 1988-2008 indicates that Hispanics/Latinos with NSCLC have a higher overall survival ...

Receiving curative lung cancer surgery varies by state

November 13, 2015
The likelihood of receiving curative-intent surgery for patients with early-stage non-small cell lung cancer (NSCLC) varies substantially from state to state, according to data presented at the Eighth American Association ...

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.